Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin1, Arkadiusz Z Dudek, Theodore F Logan, Raymond S Lance, Jeffrey M Holzbeierlein, Jennifer J Knox, Viraj A Master, Sumanta K Pal, Wilson H Miller, Lawrence I Karsh, Irina Y Tcherepanova, Mark A DeBenedette, W Lee Williams, Douglas C Plessinger, Charles A Nicolette and Robert A Figlin - Journal for Immunotherapy of Cancer 2015, 3:14
Long-Term Survival Achieved in Unfavorable Risk mRCC Patients Treated With a Combination of Autologous Immunotherapy (AGS-003) Plus Sunitinib
A. Amin, A.Z. Dudek, G. Jha2, T. Logan, R.S. Lance, J.M. Holzbeierlein, V.A. Master, S.K. Pal, J.J. Knox, L. Karsh, D. Plessinger, C.A. Nicolette, R.A. Figlin, AGS-003-006 Study Group. ASCO 2014 Genitourinary Cancers Symposium – May 30-June 3, 2014 – Chicago, IL. Abstract #4524
Enrollment Insights in the Synchronous mRCC Population: an Update From the Ongoing ADAPT* Phase 3 Study Experience
Robert A. Figlin, Christopher G. Wood, and the ADAPT Study Group. ASCO 2014 Genitourinary Cancers Symposium – May 30-June 3, 2014 – Chicago, IL. Poster #162A
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
J Ko, T K Choueiri, B I Rini, J-L Lee, N Kroeger, S Srinivas, L C Harshman, J J Knox, G A Bjarnason, M J MacKenzie, L Wood, U N Vaishampayan, N Agarwal, S K Pal, M-H Tan, S Y Rha, T Yuasa, F Donskov, A Bamias and D Y C Heng. Br J Cancer. 1 April 2014:1-6. www.bjcancer.com
Prolonged Survival with Personalized Immunotherapy (AGS-003) in Combination with Sunitinib in Unfavorable Risk Metastatic RCC (mRCC)
A. Amin, A.Z. Dudek, T. Logan, R.S. Lance, J.M. Holzbeierlein, V.A. Master, S.K. Pal, J.J.Knox, L.I. Karsh, D. Plessinger, C.A. Nicolette, R.A. Figlin, AGS-003-006 Study Group. ASCO 2013 Genitourinary Cancers Symposium – February 14-16, 2013 – Orlando FL. Abstract # 357.
Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro
M. A. DeBenedette, D. M. Calderhead, I. Y. Tcherepanova, C. A. Nicolette, and D. G. Healey, J Immunother Volume 34, Number 1, January 2011, pgs 45-57. www.immunotherapy-journal.com
Priming of a novel subset of CD28: rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells Is IL-12 dependent.
Mark A. DeBenedette, David M. Calderhead, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. The Journal of Immunology, 2008, 181: 5296–5305.
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak and M E Gore, British Journal of Cancer (2013) 108, 2470–2477 | doi: 10.1038/bjc.2013.236. www.bjcancer.com
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark A. Warren, Ali Reza Golshayan, Chakshu Sahi, Bernhard J. Eigl, J. Dean Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N. Chi, Christian Kollmannsberger, David F. McDermott, William K. Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, and Toni K. Choueiri. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.
First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).
Daniel Y.C. Heng et. al. General Poster Session, Genitourinary (Nonprostate) Cancer, J Clin Oncol 31, 2013 (suppl; abstr 4586)
Fifty genome sequences reveal breast cancer´s complexity
Meredith Wadman. Published online 2 April 2011 | Nature | doi:10.1038/news.2011.203
Final Analysis of a Phase 2 Study of an Autologous Dendritic Cell Immunotherapy (AGS-004) Showed Positive Outcomes in Primary Endpoint of Viral Load Control, and Favorable Safety and Immunogenicity Profile, in Subjects Undergoing Structured Treatment Interruption of ART.
Jean-Pierre Routy, J. Angel , S. Vezina, C. Tremblay, M. Loutfy, J. Gill, J. Baril, F. Smaill, M.-R. Boulassel, I.Y. Tcherepanova, M. DeBenedette, R.G. Jain, C.A. Nicolette and members of the AGS 004-001 study group. 18th Conference on Retroviruses and Opportunistic Infections (2011) Boston MA USA Poster
Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, David Calderhead, Joe Horvatinovich, Don Healey, Charles A Nicolette. PLoS ONE 3(1): e1489. doi:10.1371/journal.pone.0001489 2008. Read more
Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
Routy JP, Nicolette C. Immunotherapy. 2010 Jul; 2(4):467-76.